Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 2/2016

Content (12 Articles)

Original Article

Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma

Henry M. Smilowitz, Peggy L. Micca, Daniel Sasso, Qian Wu, Nathanial Dyment, Crystal Xue, Lynn Kuo

Original Article

Neutrophil–lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy

Ban Seok Lee, Sang Hyub Lee, Jun Hyuk Son, Dong Kee Jang, Kwang Hyun Chung, Yoon Suk Lee, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim

Original Article

A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer

Masanori Noguchi, Fukuko Moriya, Noriko Koga, Satoko Matsueda, Tetsuro Sasada, Akira Yamada, Tatsuyuki Kakuma, Kyogo Itoh

Open Access Original Article

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study

Susanna Mandruzzato, Sven Brandau, Cedrik M. Britten, Vincenzo Bronte, Vera Damuzzo, Cécile Gouttefangeas, Dominik Maurer, Christian Ottensmeier, Sjoerd H. van der Burg, Marij J. P. Welters, Steffen Walter

Original Article

Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery

Michael J. Campa, M. Anthony Moody, Ruijun Zhang, Hua-Xin Liao, Elizabeth B. Gottlin, Edward F. Patz Jr.

Original Article

Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients

Anastasia Dielmann, Anne Letsch, Anika Nonnenmacher, Kurt Miller, Ulrich Keilholz, Antonia Busse

Original Article

IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells

Yosuke Ohno, Hidemitsu Kitamura, Norihiko Takahashi, Junya Ohtake, Shun Kaneumi, Kentaro Sumida, Shigenori Homma, Hideki Kawamura, Nozomi Minagawa, Susumu Shibasaki, Akinobu Taketomi

Original Article

Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy

Anirudh Saraswathula, Elizabeth A. Reap, Bryan D. Choi, Robert J. Schmittling, Pamela K. Norberg, Elias J. Sayour, James E. Herndon II, Patrick Healy, Kendra L. Congdon, Gerald E. Archer, Luis Sanchez-Perez, John H. Sampson

Original Article

Galectin-1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread

Sharad Chawla, Timothy A. Warren, Leesa F. Wockner, Duncan L. J. Lambie, Ian S. Brown, Thomas P. C. Martin, Rajiv Khanna, Graham R. Leggatt, Benedict J. Panizza

Original Article

Poly(I:C) potentiates Bacillus Calmette–Guérin immunotherapy for bladder cancer

Cherifa Ayari, Marjorie Besançon, Alain Bergeron, Hélène LaRue, Vanessa Bussières, Yves Fradet

Meeting Report

8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015—May 20–22, Vancouver, Canada

Jeanette E. Boudreau, Maartje C. A. Wouters, Connie M. Krawczyk

ACKNOWLEDGEMENT TO REVIEWERS

Acknowledgement

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine